Page 2 - Kirti Jain News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kirti jain. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kirti Jain Today - Breaking & Trending Today

Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer


Estrogen receptor (ER) is present in 85% of all breast cancers, and more than 90% of ER+ positive breast cancers also contain the AR which has been demonstrated to be an important therapeutic target in ER+ breast cancer. Enobosarm is an oral drug that selectively targets the AR in breast cancer without having the unwanted virilizing androgen adverse side effects including facial hair, acne, increase in hematocrit, or liver toxicity, while having potential clinical benefits including increasing muscle and physical function as well addressing cancer treatment induced bone loss and fractures. Enobosarm has extensive nonclinical and clinical experience having been evaluated in 25 separate clinical studies with 2,091 enrolled patients, including three Phase 2 clinical studies in advanced breast cancer. There are also at least two enobosarm investigator-initiated Phase 2 clinical studies in advanced breast cancer. ....

San Antonio , United States , Baylor University , United Kingdom , San Francisco , North Adelaide , South Australia , New South Wales , Dana Farber Cancer Institute , University Of California San Francisco , Mitchell Steiner , Patrick Cobb , Carlo Palmieri , Adam Brufsky , Beth Overmoyer , Joycea Oshaughnessy , Hannah Linden , Lees Schwartzberg , Charles Vogel , Stephen Birrell , Kirti Jain , Sam Fisch , University Of Washington Seattle Cancer Care Associates , Clatterbridge Cancer Centre , University Of Pittsburgh Medical Center , Wellend Health Burside Hospital ,